Company / Interest Expense
LIGAND PHARMACEUTICALS INC Interest Expense History
FY2016-FY2023 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Interest Expense
$656.0K
FY2023
5-year range
$656.0K / $19.6M
FY2019-FY2023
Trend
-63.5%
vs FY2022
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Interest Expense has declined for 5 consecutive years, from $48M in FY2018 to $656,000 in FY2023.
Based on SEC 10-K filings.
$656,000 in FY2023 with a 5-year CAGR of -57.7%.
Improved from $20M to $656,000 over the past 2 years.
Interest Expense over time
Growth rates
- 3-Year CAGR
- -71.2%
- 5-Year CAGR
- -57.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- LIGAND PHARMACEUTICALS INC's interest expense has declined for 5 consecutive years.
- 5-year CAGR of -57.7%, indicating a declining trend.
- In FY2023, interest expense decreased 63.5% year-over-year.
- Peak interest expense was recorded in FY2018.
Company context
Key Data Points
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Interest ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | $656.0K | -63.5% |
| FY2022 | $1.8M | -90.8% |
| FY2021 | $19.6M | -28.4% |
| FY2020 | $27.4M | -23.3% |
| FY2019 | $35.7M | -26.0% |
| FY2018 | $48.3M | +258.7% |
| FY2017 | $13.5M | +4.8% |
| FY2016 | $12.8M | - |
As of FY2023 · SEC 10-K · Updated Jun 29, 2026